varsetatug masetecan ("Varseta-M") — FDA meeting
2026
FDA interactions are planned in 2026 with goal of aligning on the potential first registrational study for Varseta-M monotherapy in advanced CRC starting in 1H 2027.Source filing
CTMX biotech catalysts & pipeline
CYTOMX THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
varsetatug masetecan ("Varseta-M") — Topline data
Late 2026
Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026.Source filing
CX-801 — Initial data
H1 2027
Initial clinical data for CX-801 in combination with KEYTRUDA® in advanced melanoma is expected in the first half of 2027.Source filing
Varseta-M — Initial data
1H 2027
Initial clinical data is anticipated in 1H 2027.Source filing
varsetatug masetecan ("Varseta-M") — Initial data
1H 2027
Initial clinical data are anticipated by 1H 2027.Source filing
Varseta-M — Conference presentation
2026
• Additional Phase 1 follow-up data are also expected to be presented at major medical meeting(s) in 2026.Source filing